VivoSim Labs FY26 other income swings to USD 2.35 million expense; revenue rises 10% to USD 131,000
VIVS•Revenue and other income
VivoSim Labs posted royalty revenue of USD 131,000, up 10% year over year, with product revenue at no revenue after ending Mosaic operations in fiscal 2025.
Other results swung to a USD 2.35 million expense from USD 10.13 million income, driven by a USD 2.7 million loss tied to the March 2026 offering.
Expenses and cash position
Research and development expense fell 17% to USD 4.19 million, while selling, general and administrative costs eased 4% to USD 7.43 million.
Cash and cash equivalents dropped to USD 5 million at March 31, 2026, with operating cash outflow widening to USD 10.83 million.
Business focus and toxicology data
VivoSim pivoted to liver and intestinal toxicology services using 3D human tissue NAM models, citing 87.5% sensitivity and 100% specificity in May 2025 liver-tox data.
